VERV Verve Therapeutics
- 6.350
- +0.120+1.93%
Verve Therapeutics News
Verve Therapeutics Gains as COO Buys Shares
Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket
06:50 AM EDT, 05/16/2024 (MT Newswires) -- Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket Price: 6.65, Change: +0.42, Percent Change: +6.7
Verve Therapeutics(VERV.US) Officer Buys US$475.76K in Common Stock
$Verve Therapeutics(VERV.US)$ Officer Ashe Andrew D. purchased 76,000 shares of common stock on May 14, 2024 at an average price of $6.26 for a total value of $475.76K.Source: Announcement What is sta
Buy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong Financials
Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week
HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Verve Therapeutics (NASDAQ:VERV) with a Buy and maintains $15 price target.
Verve Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 137.34% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/03/2024 532.91% Stifel $56 → $40 Main
RBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)
Buy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth Potential
Verve Therapeutics' Financial Outlook Threatened by CRISPR Patent Disputes
Buy Rating Affirmed for Verve Therapeutics Amid Progress and Promising Pipeline
Verve Therapeutics (VERV.US): The 2024 Q1 financial report achieved revenue of US$5.695,000, with a previous value of US$1.404 million and an expected value of US$2.02 million; earnings per share were -0.59 dollars, previous value of -0.84 dollars, and ex
Verve Therapeutics (VERV.US): The 2024 Q1 financial report achieved revenue of US$5.695,000, with a previous value of US$1.404 million and an expected value of US$2.02 million; earnings per share were -0.59 dollars, previous value of -0.84 dollars, and expected value of -0.71 dollars.
Verve Therapeutics | 10-Q: Quarterly report
Verve Therapeutics 1Q Rev $5.7M >VERV
Verve Therapeutics 1Q Rev $5.7M >VERV
Verve Therapeutics 1Q Loss/Shr 59c >VERV
Verve Therapeutics 1Q Loss/Shr 59c >VERV
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102VERVE-201 clinical trial initiation on track for the second half of 2024Received first milestone payment from Eli Lilly for collabora
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
VERVE-102 is an investigational in vivo base editing medicine designed to permanently inactivate the PCSK9 gene in the liver to durably reduce blood low-density lipoprotein cholesterolHeart-2 enrollin
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing me
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...
Analysis
Price Target
No Data
